Latest filing published 23 Nov 2021 for Theravance Biopharma, Inc., €38k.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Vijay Sabesan: trading record in brief
This profile gathers the share dealings of Vijay Sabesan in Theravance Biopharma, Inc., where the filings describe the role as chief executive. Over a trading history stretching from 20 February 2019 to 19 November 2021, the count stands at 15 filings.
Every open-market trade on record is a sale: 1 sale worth €19k. The rest of the record consists of 14 share grants.
On 23 November 2021 came the latest disclosure, a share grant for €38k in Theravance Biopharma, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Vijay Sabesan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,191 shares@ US$8.3621.7% of flowOrdinary SharesSEC:0001415889-21-005464:0
- 5,193 shares@ US$14.0535.4% of flowOrdinary SharesSEC:0001179110-21-008400:0
- 5,194 shares@ US$17.8042.9% of flowOrdinary SharesSEC:0001179110-21-005848:0
3 of 3 declarations
